DEA Announces New Production Quotas for Psychedelic Substances for 2021, 2022

The DEA announced in September that it would be increasing the production quotas for Schedule I substances such as DMT, MDMA and psilocybin. This was after revealing the agency’s objective to produce more psychedelic substances for purposes of research next year. By the end of 2021, the DEA wants 6,000 grams of psilocybin to be manufactured, which is four times its last production quota.

In its proposal, the agency states that the production quota for DMT and MDMA will be increased to 3,200 grams from 50 grams each. It also wants 2 million grams of cannabis to be produced this year, which is less than the 3.2 million grams of marijuana it proposed for 2022. In addition to this, the 2022 production quota of LSD is set to increase to 500 grams from 40 grams, while that of mescaline will increase to 100 grams from 25 grams.

In a notice that will be published in the coming week, the DEA noted that the significant increase in the production quota of these Schedule I drugs occurred after the agency received additional researcher protocols from registered researchers under the DEA and quota applications from manufacturers registered under the agency.  These increases demonstrate a willingness from the federal drug enforcement agency to promote research on hallucinogenic substances, regardless of their status under the Controlled Substances Act, and recognize the growing scientific field.

Many believe that meeting these new production quotas will be made easier now that the DEA has also announced that it will be terminating the monopoly on the authorized manufacture of marijuana, by approving additional cultivators for research. For the last five decades or so, only the University of Mississippi was federally authorized for marijuana manufacturing.

In a recent interview, Nora Volkow, director of the National Institute on Drug Abuse, stated that the suggested increase in production quota for these substances was encouraging, noting that studies which showed the therapeutic benefits of psychedelic substances could prompt more individuals to experiment with the substances.

Despite this progress, however, advocates want these entheogenic fungi and plants to be decriminalized and/or legalized soon. Currently, the substances remain categorized in the strictest category in the Controlled Substances Act, despite research demonstrating their medical value for certain conditions.

For instance, research has found that psilocybin has the potential to be used as a treatment for anxiety and depression while LSD has been found effective in the treatment of addiction. Additionally, research has found that MDMA may have the potential to treat severe post-traumatic stress disorder.

This production increase means that more entities are likely to join the ranks of Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) and other companies studying different psychedelics with a view to developing medicinal formulations from them.

NOTE TO INVESTORS: The latest news and updates relating to Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050